| | |
Unadjusted estimates, mean (SD)
|
Adjusted analysis for intervention vs usual carea
|
|---|
|
Intervention group
|
Control group
|
Intervention group
|
Control group
|
P value1)
|
|---|
|
MET/h/day
|
Baseline
|
26.7 (27.5)
|
27.5 (19.8)
| | | |
|
3 months
|
27.1 (25.4)
|
24.3 (24.6)
|
26.2 (2.2)
|
23.9 (3.0)
|
0.540
|
|
12 months
|
23.5 (23.6)
|
22.9 (24.6)
|
22.9 (2.3)
|
22.8 (3.3)
|
0.975
|
|
PTGI-Total
|
Baseline
|
63.1 (18.5)
|
61.8 (18.9)
| | | |
|
3 months
|
63.6 (19.3)
|
61.2 (18.6)
|
62.7 (1.3)
|
62.1 (1.7)
|
0.791
|
|
12 months
|
66.6 (19.3)
|
60.2 (19.1)
|
66.3 (1.6)
|
61.2 (2.2)
|
0.065*
|
|
Vegetable intake n(%), ≥5 serves/day
|
Baseline
|
45 (33.6)
|
22 (30.6)
| | | |
|
3 months
|
52 (42.6)
|
27 (40.9)
|
33.6 (4.9)
|
31.0 (6.3)
|
0.819
|
|
12 months
|
41 (36.9)
|
26 (42.6)
|
31.0 (5.4)
|
37.3 (6.7)
|
0.413
|
|
Leadership
|
Baseline
|
121.3 (21.2)
|
120.1 (20.8)
| | | |
|
3 months
|
125.0 (21.7)
|
121.6 (20.2)
|
123.1 (1.3)
|
121.8 (1.9)
|
0.552
|
|
12 months
|
127.7 (22.1)
|
122.8 (20.6)
|
125.4 (1.6)
|
123.3 (2.2)
|
0.433
|
|
HADS
|
|
Anxiety
|
Baseline
|
5.7 (3.4)
|
5.9 (3.1)
| | | |
|
3 months
|
5.0 (3.0)
|
6.1 (3.1)
|
5.2 (0.2)
|
6.0 (0.3)
|
0.025**
|
|
12 months
|
5.1 (3.0)
|
5.8 (2.9)
|
5.2 (0.3)
|
5.7 (0.4)
|
0.228
|
|
Depression
|
Baseline
|
6.4 (3.5)
|
6.1 (3.1)
| | | |
|
3 months
|
5.5 (3.3)
|
5.4 (2.8)
|
5.6 (0.2)
|
5.6 (0.3)
|
0.986
|
|
12 months
|
5.4 (3.4)
|
5.6 (3.1)
|
5.3 (0.3)
|
5.7 (0.4)
|
0.428
|
|
EORTC QLQ-C30
|
|
Functional scales
|
|
Global health status
|
Baseline
|
64.5 (19.9)
|
63.4 (18.7)
| | | |
|
3 months
|
67.7 (18.7)
|
65.7 (17.5)
|
67.0 (1.6)
|
66.0 (2.3)
|
0.705
|
|
12 months
|
70.1 (17.1)
|
65.3 (17.9)
|
69.0 (1.6)
|
66.0 (2.2)
|
0.269
|
|
Physical functioning
|
Baseline
|
78.6 (13.5)
|
77.9 (11.1)
| | | |
|
3 months
|
80.0 (12.1)
|
78.4 (12.0)
|
79.4 (0.9)
|
79.3 (1.3)
|
0.942
|
|
12 months
|
82.9 (13.1)
|
78.2 (12.4)
|
81.9 (1.2)
|
78.7 (1.6)
|
0.123
|
|
Role functioning
|
Baseline
|
79.4 (21.4)
|
77.9 (19.8)
| | | |
|
3 months
|
80.9 (18.1)
|
77.3 (18.4)
|
80.3 (1.5)
|
78.5 (2.2)
|
0.497
|
|
12 months
|
82.7 (19.8)
|
79.9 (18.9)
|
80.9 (1.8)
|
81.1 (2.4)
|
0.958
|
|
Emotional functioning
|
Baseline
|
76.8 (19.4)
|
73.0 (23.0)
| | | |
|
3 months
|
78.0 (19.1)
|
74.5 (16.5)
|
76.7 (1.5)
|
75.3 (2.2)
|
0.602
|
|
12 months
|
78.0 (19.9)
|
75.9 (18.3)
|
76.2 (1.9)
|
77.7 (2.4)
|
0.625
|
|
Cognitive functioning
|
Baseline
|
76.7 (19.9)
|
72.6 (20.9)
| | | |
|
3 months
|
80.1 (17.2)
|
72.5 (20.2)
|
77.6 (1.4)
|
75.1 (2.4)
|
0.322
|
|
12 months
|
78.1 (14.9)
|
76.5 (19.2)
|
76.8 (1.6)
|
78.4 (2.1)
|
0.552
|
|
Social functioning
|
Baseline
|
75.8 (26.8)
|
73.1 (23.4)
| | | |
|
3 months
|
85.4 (19.3)
|
76.3 (20.2)
|
84.8 (1.8)
|
77.4 (2.5)
|
0.018
|
|
12 months
|
85.3 (19.5)
|
78.2 (22.4)
|
84.8 (2.2)
|
79.0 (2.9)
|
0.123
|
|
Symptom scales
|
|
Fatigue
|
Baseline
|
38.6 (20.9)
|
40.8 (21.6)
| | | |
|
3 months
|
33.5 (17.8)
|
38.1 (17.7)
|
34.3 (1.5)
|
37.6 (2.2)
|
0.214
|
|
12 months
|
33.8 (16.1)
|
42.4 (21.4)
|
34.8 (1.6)
|
41.9 (2.1)
|
0.010**
|
|
Nausea/vomiting
|
Baseline
|
4.6 (10.0)
|
4.2 (10.6)
| | | |
|
3 months
|
5.7 (10.6)
|
5.3 (9.8)
|
5.6 (0.9)
|
6.2 (1.3)
|
0.733
|
|
12 months
|
6.4 (14.5)
|
7.8 (15.3)
|
6.5 (1.6)
|
7.7 (2.1)
|
0.660
|
|
Pain
|
Baseline
|
15.4 (19.2)
|
21.4 (19.0)
| | | |
|
3 months
|
11.9 (16.0)
|
19.6 (19.6)
|
13.6 (1.5)
|
17.4 (2.1)
|
0.146
|
|
12 months
|
13.1 (17.6)
|
19.7 (21.4)
|
15.5 (1.8)
|
16.2 (2.3)
|
0.810
|
|
Dyspnea
|
Baseline
|
11.9 (19.9)
|
19.4 (21.0)
| | | |
|
3 months
|
8.2 (15.9)
|
13.7 (16.6)
|
10.3 (1.3)
|
11.3 (1.9)
|
0.668
|
|
12 months
|
10.6 (19.5)
|
13.6 (17.9)
|
12.1 (2.0)
|
11.3 (2.6)
|
0.797
|
|
Insomnia
|
Baseline
|
28.8 (30.0)
|
30.3 (28.9)
| | | |
|
3 months
|
24.1 (24.50
|
26.7 (26.9)
|
25.0 (2.1)
|
25.7 (3.1)
|
0.850
|
|
12 months
|
26.2 (27.9)
|
32.0 (27.2)
|
27.6 (2.5)
|
29.1 (3.4)
|
0.732
|
|
Appetite loss
|
Baseline
|
12.8 (20.9)
|
15.4 (24.8)
| | | |
|
3 months
|
10.7 (17.6)
|
17.3 (23.6)
|
11.3 (1.8)
|
17.7 (2.6)
|
0.048
|
|
12 months
|
11.6 (17.6)
|
13.6 (20.3)
|
12.1 (2.0)
|
13.7 (2.6)
|
0.631
|
|
Constipation
|
Baseline
|
16.9 (26.7)
|
18.9 (24.1)
| | | |
|
3 months
|
14.7 (23.3)
|
16.3 (21.6)
|
16.5 (1.8)
|
16.0 (2.7)
|
0.882
|
|
12 months
|
12.6 (18.1)
|
17.7 (20.5)
|
19.5 (2.2)
|
16.5 (2.9)
|
0.414
|
|
Diarrhea
|
Baseline
|
13.8 (20.7)
|
11.4 (18.8)
| | | |
|
3 months
|
12.6 (18.1)
|
14.0 (17.9)
|
19.8 (4.1)
|
10.0 (5.4)
|
0.151
|
|
12 months
|
20.5 (45.6)
|
9.5 (20.4)
|
11.9 (1.5)
|
15.3 (2.2)
|
0.211
|
|
Financial Difficulties
|
Baseline
|
20.3 (28.6)
|
23.4 (26.0)
| | | |
|
3 months
|
15.5 (25.5)
|
26.8 (37.1)
|
17.4 (2.6)
|
27.0 (3.7)
|
0.036 **
|
|
12 months
|
18.9 (26.6)
|
20.4 (27.9)
|
18.9 (2.5)
|
19.3 (3.3)
|
0.920
|
|
The MOS-SSS
|
Baseline
|
65.6 (20.9)
|
65.6 (20.6)
| | | |
|
3 months
|
66.3 (21.1)
|
67.9 (19.3)
|
66.9 (1.4)
|
65.7 (2.0)
|
0.621
|
|
12 months
|
66.6 (21.1)
|
68.0 (19.7)
|
67.1 (1.7)
|
65.3 (2.4)
|
0.535
|
|
Health Behavior
|
Baseline
|
4.9 (3.1)
|
5.2 (2.7)
| | | |
|
3 months
|
6.4 (2.7)
|
5.5 (3.0)
|
6.9 (0.3)
|
6.2 (0.4)
|
0.147
|
|
12 months
|
7.0 (2.8)
|
6.3 (2.7)
|
6.3 (0.2)
|
5.3 (0.3)
|
0.015**
|
|
IES-R
|
Baseline
|
2.3 (0.8)
|
2.5 (0.7)
| | | |
|
3 months
|
2.2 (0.7)
|
2.2 (0.7)
|
2.3 (0.1)
|
2.2 (0.1)
|
0.759
|
|
12 months
|
2.1 (0.7)
|
2.3 (0.8)
|
2.1 (0.1)
|
2.3 (0.1)
|
0.068 *
|
-
aAdjusted baseline value with a statistical power of 80% and an effect size of 0.3 by a two-sided t test at the 0.05 α level was used
- *p < 0.10 with bold
- **p < 0.05 with bold
-
1)ANCOVA
-
MET Metabolic Equivalent Task, PTGI Post-traumatic Growth Inventory, HADS Hospital and Anxiety Scale, EROTC QLQ-C30 European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30, MOS-SSS Medical Outcomes Study Social Support Survey, IES-R Impact of Event Scale--Revised
